KRAS G12C clinical trials at UC Davis

1 research study open to eligible people

Showing trials for

  • BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18 years and up

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

    Sacramento, California and other locations

Last updated: